Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales | CYTK Stock NewsStockTitan·9 hours agoCYTK-1.34%
Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To CompetitorsMarketWatch Automated·15 hours agoVRTX-1.44%
Revolution Medicines to report Q2 financial results after market close, hosts webcast updatePUBT·15 hours agoRVMD-1.60%
AbCellera partners with Vertex to develop multispecific T-cell engagers for autoimmune diseases, other conditionsPUBT·1 day ago, 06:04 AMVRTX-1.44%ABCL+1.89%
Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily GainsMarketWatch Automated·1 day ago, 03:38 PMVRTX-1.44%
Is Cytokinetics (CYTK) Cheap Or Has Its Cardiac Growth Story Already Been Priced In?Simplywall·2 days ago, 02:23 AMCYTK-1.34%
Illumina Inc. Stock Underperforms Monday When Compared To CompetitorsMarketWatch Automated·2 days ago, 04:24 PMILMN+0.95%
Cytokinetics CEO Robert I. Blum disposes of 7,500 common shares for $606,525PUBT·2 days ago, 03:34 PMCYTK-1.34%
ABN Amro Investment Solutions Purchases Shares of 6,794 Revolution Medicines, Inc. $RVMDMarket Beat·Jul 26 at 02:04 AMRVMD-1.60%JHG0.00%
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by PNC Financial Services Group Inc.Market Beat·Jul 25 at 04:04 AMVRTX-1.44%
New AI ETF Bets on Healthcare's $9 Trillion Opportunitybenzinga_article·Jul 24 at 02:08 PMHLTH+0.63%CYTK-1.34%
Hsbc Holdings PLC Makes New Investment in 10x Genomics $TXGMarket Beat·Jul 24 at 03:50 AMTXG-1.55%HSBA
Illumina Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily GainsMarketWatch Automated·Jul 23 at 04:24 PMILMN+0.95%
Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $282,065PUBT·Jul 23 at 03:10 PMCYTK-1.34%
